Literature DB >> 18353771

Guinea pig chymase is leucine-specific: a novel example of functional plasticity in the chymase/granzyme family of serine peptidases.

George H Caughey1, Jeremy Beauchamp, Daniel Schlatter, Wilfred W Raymond, Neil N Trivedi, David Banner, Harald Mauser, Jürgen Fingerle.   

Abstract

To explore guinea pigs as models of chymase biology, we cloned and expressed the guinea pig ortholog of human chymase. In contrast to rats and mice, guinea pigs appear to express just one chymase, which belongs to the alpha clade, like primate chymases and mouse mast cell protease-5. The guinea pig enzyme autolyzes at Leu residues in the loop where human chymase autolyzes at Phe. In addition, guinea pig alpha-chymase selects P1 Leu in a combinatorial peptide library and cleaves Ala-Ala-Pro-Leu-4-nitroanilide but has negligible activity toward substrates with P1 Phe and does not cleave angiotensin I. This contrasts with human chymase, which cleaves after Phe or Tyr, prefers P1 Phe in peptidyl 4-nitroanilides, and avidly hydrolyzes angiotensin I at Phe8 to generate bioactive angiotensin II. The guinea pig enzyme also is inactivated more effectively by alpha1-antichymotrypsin, which features P1 Leu in the reactive loop. Unlike mouse, rat, and hamster alpha-chymases, guinea pig chymase lacks elastase-like preference for P1 Val or Ala. Partially humanized A216G guinea pig chymase acquires human-like P1 Phe- and angiotensin-cleaving capacity. Molecular models suggest that the wild type active site is crowded by the Ala216 side chain, which potentially blocks access by bulky P1 aromatic residues. On the other hand, the guinea pig pocket is deeper than in Val-selective chymases, explaining the preference for the longer aliphatic side chain of Leu. These findings are evidence that chymase-like peptidase specificity is sensitive to small changes in structure and provide the first example of a vertebrate Leu-selective peptidase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353771      PMCID: PMC2376239          DOI: 10.1074/jbc.M710502200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  A despecialization step underlying evolution of a family of serine proteases.

Authors:  Merridee A Wouters; Ke Liu; Peter Riek; Ahsan Husain
Journal:  Mol Cell       Date:  2003-08       Impact factor: 17.970

2.  Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle.

Authors:  J Pablo Abonia; Daniel S Friend; William G Austen; Francis D Moore; Michael C Carroll; Rodney Chan; Jalil Afnan; Alison Humbles; Craig Gerard; Pamela Knight; Yoshihide Kanaoka; Shinsuke Yasuda; Nasa Morokawa; K Frank Austen; Richard L Stevens; Michael F Gurish
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

3.  Angiotensin II generation by mast cell alpha- and beta-chymases.

Authors:  G H Caughey; W W Raymond; P J Wolters
Journal:  Biochim Biophys Acta       Date:  2000-07-14

4.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries.

Authors:  J L Harris; B J Backes; F Leonetti; S Mahrus; J A Ellman; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

5.  Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors.

Authors:  J C Powers; T Tanaka; J W Harper; Y Minematsu; L Barker; D Lincoln; K V Crumley; J E Fraki; N M Schechter; G G Lazarus
Journal:  Biochemistry       Date:  1985-04-09       Impact factor: 3.162

6.  A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.

Authors:  Lawrence de Garavilla; Michael N Greco; Narayanasami Sukumar; Zhi-Wei Chen; Agustin O Pineda; F Scott Mathews; Enrico Di Cera; Edward C Giardino; Grace I Wells; Barbara J Haertlein; Jack A Kauffman; Thomas W Corcoran; Claudia K Derian; Annette J Eckardt; Bruce P Damiano; Patricia Andrade-Gordon; Bruce E Maryanoff
Journal:  J Biol Chem       Date:  2005-02-28       Impact factor: 5.157

7.  Rodent alpha-chymases are elastase-like proteases.

Authors:  Yuichi Kunori; Masahiro Koizumi; Tsukio Masegi; Hidenori Kasai; Hiroshi Kawabata; Yuzo Yamazaki; Akiyoshi Fukamizu
Journal:  Eur J Biochem       Date:  2002-12

8.  Involvement of chymase-mediated angiotensin II generation in blood pressure regulation.

Authors:  Ming Li; Ke Liu; Jan Michalicek; James A Angus; John E Hunt; Louis J Dell'Italia; Michael P Feneley; Robert M Graham; Ahsan Husain
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  The extended cleavage specificity of the rodent beta-chymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase.

Authors:  Mattias K Andersson; Ulrika Karlson; Lars Hellman
Journal:  Mol Immunol       Date:  2007-08-06       Impact factor: 4.407

10.  Specificity of human cathepsin G.

Authors:  J Polanowska; I Krokoszynska; H Czapinska; W Watorek; M Dadlez; J Otlewski
Journal:  Biochim Biophys Acta       Date:  1998-07-28
View more
  12 in total

Review 1.  Mast cell peptidases: chameleons of innate immunity and host defense.

Authors:  Neil N Trivedi; George H Caughey
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-20       Impact factor: 6.914

Review 2.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

3.  Remodeling of intrinsic cardiac neurons: effects of β-adrenergic receptor blockade in guinea pig models of chronic heart disease.

Authors:  Jean C Hardwick; E Marie Southerland; Allison E Girasole; Shannon E Ryan; Sara Negrotto; Jeffrey L Ardell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-08-29       Impact factor: 3.619

4.  How immune peptidases change specificity: cathepsin G gained tryptic function but lost efficiency during primate evolution.

Authors:  Wilfred W Raymond; Neil N Trivedi; Anastasia Makarova; Manisha Ray; Charles S Craik; George H Caughey
Journal:  J Immunol       Date:  2010-10-01       Impact factor: 5.422

5.  Mutational tail loss is an evolutionary mechanism for liberating marapsins and other type I serine proteases from transmembrane anchors.

Authors:  Kavita Raman; Neil N Trivedi; Wilfred W Raymond; Rajkumar Ganesan; Daniel Kirchhofer; George M Verghese; Charles S Craik; Eric L Schneider; Shilpa Nimishakavi; George H Caughey
Journal:  J Biol Chem       Date:  2013-02-27       Impact factor: 5.157

6.  Estrogen modulates the differential expression of cardiac myocyte chymase isoforms and diastolic function.

Authors:  Hao Wang; Xuming Sun; Sarfaraz Ahmad; Jing Su; Carlos Maria Ferrario; Leanne Groban
Journal:  Mol Cell Biochem       Date:  2019-02-02       Impact factor: 3.396

7.  The Importance of Exosite Interactions for Substrate Cleavage by Human Thrombin.

Authors:  Gurdeep Chahal; Michael Thorpe; Lars Hellman
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

8.  Extended cleavage specificity of human neutrophil cathepsin G: A low activity protease with dual chymase and tryptase-type specificities.

Authors:  Michael Thorpe; Zhirong Fu; Gurdeep Chahal; Srinivas Akula; Jukka Kervinen; Lawrence de Garavilla; Lars Hellman
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

9.  Mutations in Arg143 and Lys192 of the Human Mast Cell Chymase Markedly Affect the Activity of Five Potent Human Chymase Inhibitors.

Authors:  Parvin Ahooghalandari; Nina Hanke; Michael Thorpe; Andreas Witte; Josef Messinger; Lars Hellman
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

10.  Extended cleavage specificities of two mast cell chymase-related proteases and one granzyme B-like protease from the platypus, a monotreme.

Authors:  Zhirong Fu; Srinivas Akula; Michael Thorpe; Lars Hellman
Journal:  Int J Mol Sci       Date:  2020-01-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.